Application of lymphocyte cytoplasm protein 1 as biomarker of atherosclerotic cardiovascular disease

By detecting the expression level of lymphocyte cytoplasmic protein 1, the problem of insufficient biomarker specificity and sensitivity in the diagnosis of atherosclerotic cardiovascular disease is solved, and the rapid and accurate diagnosis of atherosclerotic cardiovascular disease is achieved. and condition monitoring provide strong support for clinical decision-making.

CN119020479APending Publication Date: 2024-11-26梅州市人民医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411123333.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, the biomarker specificity and sensitivity of atherosclerotic cardiovascular disease are insufficient, making it difficult to achieve rapid and accurate diagnosis and disease monitoring.

Method used

Using lymphocyte cytoplasmic protein 1 (LCP1) as a novel biomarker, by detecting its mRNA and protein expression levels, it develops diagnostic reagents for atherosclerotic cardiovascular disease, and combines bioinformatics analysis and clinical data to verify its Diagnostic efficacy.

Benefits of technology

The diagnostic accuracy and distinction of atherosclerotic cardiovascular disease have been improved, and the AUC value of LCP1 reaches 0.819, which has high clinical diagnostic value and application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020479A_ABST
    Figure CN119020479A_ABST
Patent Text Reader

Abstract

The invention discloses an application of lymphocyte cytoplasm protein 1 as a biomarker of atherosclerotic cardiovascular disease. By integrating a plurality of public data sets closely related to the atherosclerosis pathological process, applying a bioinformatics analysis method and combining experimental verification, it is found that the lymphocyte cytoplasm protein 1 gene has the high expression characteristic in plaque tissue of a patient with atherosclerotic cardiovascular diseases, and the lymphocyte cytoplasm protein 1 gene has the high expression characteristic in the plaque tissue of the patient with atherosclerotic cardiovascular diseases. And the protein expression level of lymphocyte cytoplasm protein 1 in serum is obviously increased in patients with atherosclerotic cardiovascular diseases. Therefore, the lymphocyte cytoplasm protein 1 has the potential of serving as a biomarker of the atherosclerotic cardiovascular disease, and a new auxiliary means is provided for diagnosis of the atherosclerotic cardiovascular disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and more specifically, to a biomarker associated with atherosclerotic cardiovascular disease and its application. Background Art

[0002] Atherosclerotic Cardiovascular Disease (ASCVD) is a general term for a wide range of atherosclerotic diseases. The main cause of ASCVD is atherosclerosis, which is characterized by the accumulation of lipid and fibrous components in the vascular intima, leading to thickening of the arterial wall and the formation of atherosclerotic plaques. ASCVD often includes acute coronary syndrome, stable coronary heart disease, post-revascularization surgery, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, and peripheral arterial atherosclerosis ("China Cardiovascular Health and Disease Report Writing Group. Summary of China Cardiovascular Health and Disease Report 2019 [J]. Chinese Journal of Circulation, 2020, 35(9): 833-854. DOI: 10.3969 / j.issn.1000-3614.2020.09.001.").

[0003] At present, imaging techniques used to show arterial stenosis caused by atherosclerosis include duplex ultrasound, CT angiography and angiography. Compared with imaging methods, biomarker detection has the advantages of convenient operation, rapidity and easy interpretation of results. However, traditional laboratory tests for atherosclerotic cardiovascular disease include the determination of blood lipids and apolipoproteins, which can only evaluate the risk factors of atherosclerotic cardiovascular disease and cannot be used as serological markers for the diagnosis of atherosclerotic cardiovascular disease. They have the disadvantage of low specificity. Therefore, it is urgent to find low-cost, reproducible and highly specific biomarkers in clinical practice to better help diagnose and monitor the condition of patients with atherosclerotic cardiovascular disease.

[0004] Lymphocyte cytoplasmic protein 1 (LCP1), also known as L-plastin, is a highly conserved actin-binding protein in humans, mice, and zebrafish. LCP1 contains two N-terminal EF-hand structures involved in calcium binding, as well as two actin-binding domains. LCP1 contains two N-terminal phosphorylation sites: Ser5 (the main site) and Ser7. Phosphorylation enhances the targeting of LCP1 to F-actin-rich structures and increases the bundling activity of LCP1 to actin. LCP1 mainly regulates cell motility by assisting actin polymerization and cytoskeletal rearrangement, and is one of the main cytoskeleton-binding proteins that directly control cell motility. In addition, LCP1 is also involved in host defense, the formation of immune synapses, and the activation of T cells. LCP1 deficiency impairs multiple immune functions, mainly by disrupting processes that rely on adhesion-based signaling. In macrophages, LCP1 co-localizes with actin-supported structures and is concentrated in pseudopod bodies that support cell motility and adhesion. Under normal circumstances, LCP1 is mainly expressed in hematopoietic cells, including neutrophils, monocytes, macrophages, T cells, and B cells, but is highly expressed in a variety of malignant tumor cells. In tumor cells of non-hematopoietic origin, such as colorectal cancer, oral cancer, prostate cancer, and cholangiocarcinoma, high expression of LCP1 is associated with increased cell migration and invasion. Abnormal expression of LCP1 is closely related to the stage and severity of various cancers, and its abnormal expression can be used as a biomarker for tumors and a target for molecular therapy. However, the expression level of LCP1 in blood or tissue samples of patients with atherosclerotic cardiovascular disease and its diagnostic efficacy are still unclear. Summary of the invention

[0005] Based on the above problems, the purpose of the present invention is to provide a new biomarker based on LCP1, so as to solve the technical problems of insufficient specificity and sensitivity of biomarkers in the current diagnosis of atherosclerotic cardiovascular disease, achieve rapid and accurate diagnosis of the disease, and effectively monitor the progression of the disease, providing strong support for clinical decision-making.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The invention discloses application of a reagent for detecting the expression level of lymphocyte cytoplasmic protein 1 in a sample in preparing a product for diagnosing atherosclerotic cardiovascular disease.

[0008] Specifically, the present invention proposes a new biomarker LCP1 for the diagnosis of atherosclerotic cardiovascular disease. The present invention integrates multiple public data sets closely related to the pathological process of atherosclerosis and uses bioinformatics analysis methods to analyze the expression characteristics of the LCP1 gene, thereby ensuring the reliability and universality of the research results. The present invention found that LCP1 is highly expressed in human carotid artery plaque tissue at the mRNA level. By comparing the LCP1 protein levels in the peripheral blood serum of patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease populations, it was found that LCP1 was significantly elevated in patients with atherosclerotic cardiovascular disease; and ROC curve analysis revealed that the AUC value of LCP1 in the clinical diagnosis of patients with atherosclerotic cardiovascular disease reached 0.819, which has high reliability, indicating that LCP1 can be used as a potential biomarker for atherosclerotic cardiovascular disease.

[0009] Furthermore, the reagent includes:

[0010] A reagent for detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in a sample; or,

[0011] A reagent for detecting the protein expression level of lymphocyte cytoplasmic protein 1 in a sample.

[0012] Furthermore, the product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in a sample from the subject.

[0013] Furthermore, the product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the protein expression level of lymphocyte cytoplasmic protein 1 in a sample from the subject.

[0014] Furthermore, the reagents for detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in the sample include the reagents required for detecting the mRNA expression level of the lymphocyte cytoplasmic protein 1 by high-throughput RNA sequencing, RNA-in situ hybridization, digital PCR or fluorescent quantitative PCR method.

[0015] Furthermore, the reagents for detecting the protein expression level of lymphocyte cytoplasmic protein 1 in the sample include reagents required for detecting the protein expression level of the lymphocyte cytoplasmic protein 1 by chemiluminescence, immunofluorescence, protein chip, protein spectrum, immunohistochemistry, plaque tracing based on labeling technology (including but not limited to isotope-labeled antibodies or proteins, fluorescently labeled antibodies or proteins, etc.), Western blotting or enzyme-linked immunosorbent assay.

[0016] Furthermore, the sample is a serum or tissue sample.

[0017] Furthermore, the product is a detection kit.

[0018] Furthermore, the product is a detection chip.

[0019] Furthermore, the product is a test strip.

[0020] The beneficial effects of the present invention are as follows:

[0021] Compared with the prior art, the biomarker LCP1 is used for the diagnosis of atherosclerotic cardiovascular disease for the first time in the present invention. The present invention integrates multiple public data sets closely related to the pathological process of atherosclerosis, and uses bioinformatics analysis methods to analyze the expression characteristics of the LCP1 gene, thereby ensuring the reliability and universality of the research results. The present invention experimentally verifies the high expression characteristics of the LCP1 gene in plaque tissue, and the LCP1 protein level in serum is significantly increased in patients with atherosclerotic cardiovascular disease. The ROC curve analysis method evaluates the performance of serum LCP1 protein in the diagnosis of atherosclerotic cardiovascular disease. The results show that LCP1 has high diagnostic accuracy and discrimination, with an AUC value of 0.819, indicating that it has high application value in clinical diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0023] Figure 1 The expression results of LCP1 gene in different plaque type groups in datasets GSE28829, GSE163154 and GSE43292 are shown.

[0024] Figure 2 The results of evaluating the expression of LCP1 protein in the case group and the control group in the serum proteome data of Zhang et al. are shown.

[0025] Figure 3 The figure shows the expression of LCP1 in human carotid artery plaque (AP) and its adjacent tissue without plaque (PF) detected by fluorescence quantitative PCR; the left figure represents human carotid artery dissection tissue (including atherosclerotic plaque area and adjacent tissue without plaque); the right figure represents the fluorescence quantitative PCR detection results of LCP1 gene between the two groups.

[0026] Figure 4It shows that the evaluation of LCP1 in peripheral blood serum has important clinical diagnostic value in the clinical diagnosis of atherosclerotic cardiovascular disease; the left figure represents the ELISA determination of LCP1 in the serum of patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease population, and the protein concentration of LCP1 in the serum of the atherosclerotic cardiovascular disease group was significantly increased; the right figure ROC curve analysis shows that the evaluation of LCP1 in serum in the atherosclerotic cardiovascular disease group and the non-atherosclerotic cardiovascular disease group has a high credibility and can be used as a potential serum marker for atherosclerotic cardiovascular disease. DETAILED DESCRIPTION

[0027] In order to more clearly illustrate the present invention, the present invention is further described below in conjunction with preferred embodiments and accompanying drawings. Similar components in the accompanying drawings are represented by the same reference numerals. It should be understood by those skilled in the art that the content specifically described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0028] The experimental materials used in the present invention are as follows:

[0029] Reagents and consumables:

[0030] The reagents used in the present invention include: Trizol (Invitrogen), PrimeScript TM RT reagent Kit with gDNA Eraser (Takara), TB Premix Ex TagTMII (Takara), LCP1 and internal reference gene amplification primers (5'-CACTCTCACACTGGCCTTGA-3' and 5'-GAGGTCCAGAACAGGCAGAC-3' are used to amplify LCP1; 5'-CTCCTCCACCTTTGACGC-3' and 5'-CCACCACCCTGTTGCTGT-3' are used to amplify the internal reference gene GAPDH), ELISA kit (Wuhan Fine Biotechnology); the consumables used in the present invention include: pipette tips, enzyme-free EP tubes, PCR eight-tube strips and other consumables.

[0031] Experimental instruments:

[0032] Spectrophotometer (Thermo Fisher), microplate reader (Thermo Fisher), fluorescence quantitative PCR instrument (ABI) and other instruments.

[0033] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0034] The present invention provides a novel biomarker related to the diagnosis of atherosclerosis, aiming to improve the sensitivity and specificity of the diagnosis of atherosclerotic cardiovascular disease and provide a new auxiliary means for clinical diagnosis. The technical solution is mainly based on bioinformatics analysis and clinical data / sample verification, as follows:

[0035] Example 1 Analysis of the expression of LCP1 gene in atherosclerosis-related datasets

[0036] The datasets GSE28829, GSE49292, and GSE163154 related to atherosclerotic cardiovascular disease were downloaded from the public database GEO. The GSE28829 dataset contains 29 atherosclerotic plaque samples (13 early plaques and 16 advanced plaques). We observed that there were significant differences in the expression levels of the LCP1 gene between early and advanced carotid atherosclerotic plaques, and the LCP1 gene was more highly expressed in advanced plaques. The GSE163154 dataset contains hemorrhagic plaque (IPH) and non-hemorrhagic plaque (non-IPH) tissues. Similarly, the expression of the LCP1 gene in hemorrhagic plaques was significantly higher than that in non-hemorrhagic plaques. In addition, the GSE49292 dataset contains atherosclerotic plaque areas (Atheroma plaque, AP) and paired plaque-free macroscopically intact tissue (Plaque-free macroscopically intact tissue, PF) from the same patient. After analysis, it was found that the expression of the LCP1 gene in atherosclerotic plaques was significantly higher than that in non-plaque adjacent tissues (see Figure 1 ).

[0037] Zhang et al. (Rev. Cardiovasc. Med. 2022, 23(7), 229.) used proteomics technology based on data independent acquisition (DIA) to perform serum proteomics testing on 30 patients with severe coronary artery calcification and 30 matched controls. We reanalyzed the serum proteomics data of this study and found that the protein level of LCP1 detected in the serum of patients with severe coronary artery calcification was significantly higher than that in the serum of the control group (see Figure 2 ). This also suggests that LCP1 may have the ability to be secreted into peripheral blood.

[0038] Example 2 Experimental verification of LCP1 gene expression in patients with carotid artery stenosis

[0039] Sample collection: Samples obtained from 3 patients with carotid artery stenosis by carotid endarterectomy were collected and divided into two parts: carotid plaque and adjacent tissue.

[0040] RNA extraction from human carotid artery dissection tissue: take appropriate amount of tissue, cut into pieces, add liquid nitrogen and grind into powder quickly, transfer to 1mL Trizol EP tube and shake for 2h to fully lyse the tissue; centrifuge the sample at 4℃, 11000g for 10min, transfer the supernatant to a new EP tube with 200μL chloroform, shake vigorously and let stand at room temperature for 3min; centrifuge at 4℃, 11000g for 15min, transfer the colorless aqueous phase (RNA solution) to a new EP tube, add 500μL isopropanol and mix, let stand at room temperature for 10min; centrifuge at 4℃, 11000g for 10min, discard the supernatant and add 75% ethanol; centrifuge at 4℃, 7500g for 5min, discard the supernatant, dry at room temperature for 3-5min, add 25μl enzyme-free water to dissolve the total RNA, and measure the concentration.

[0041] RNA reverse transcription: Add 2μL 5×gDNA Eraser Buffer and 1μL gDNAEraser to a 200μL PCR tube, add 1μg RNA, and finally add enzyme-free water to 10μL. Flick gently, centrifuge slightly, and incubate at 42℃ in a PCR instrument for 2min to remove genomic DNA; add 1μL PrimeScript RT Enzyme Mix I, 1μL RTPrimer Mix, 4μL 5× PrimeScript Buffer 2 (for Real Time) and 4μL enzyme-free water to the above reaction solution. Flick gently, centrifuge slightly, and synthesize cDNA in the PCR instrument according to the following steps: 37℃15min, 85℃5s.

[0042] Fluorescence quantitative PCR detection: add 1 μL cDNA, 1 μL amplification primer, 3 μL enzyme-free water, 5 μL TB into a 200 μL PCR tube. Premix Ex Tag TM II, the reaction was carried out in the PCR instrument in the following steps: pre-denaturation: 95°C, 30s; PCR reaction: 95°C, 5s, 60°C, 34s, and PCR reaction was repeated for 40 cycles. After the fluorescence curve value was generated, the relative expression of the target gene was calculated according to the formula 2^-△△Ct, where △Ct = Ct (target gene) - Ct (reference gene).

[0043] like Figure 3As shown in the left figure: carotid artery dissection tissue samples can be divided into adjacent artery tissue without plaque (PF) and atherosclerotic plaque (AP). Further, in order to identify whether there is a difference in the expression of LCP1 in PF and AP, the present invention divides the carotid artery dissection tissue into PF and AP, and then quickly grinds them into powder in liquid nitrogen, extracts total RNA using Trizol method, reverse transcribes RNA, and uses fluorescent quantitative PCR technology to detect the expression of LCP1 at the mRNA level. The results are shown in Figure 2. Figure 3 As shown in the right figure: The expression of LCP1 in the carotid artery tissue containing plaque (AP) is significantly higher than that in the adjacent artery tissue without plaque (PF).

[0044] Example 3 ELISA method was used to detect the LCP1 protein level in the serum of patients with atherosclerotic cardiovascular disease and non-atherosclerotic cardiovascular disease and to evaluate the diagnostic efficacy.

[0045] Sample collection: In order to verify whether the protein encoded by the LCP1 gene has the potential to be used as a peripheral blood serum marker, the present invention collected peripheral blood serum samples from 21 patients with atherosclerotic cardiovascular disease and 10 patients with non-atherosclerotic cardiovascular disease. The level of LCP1 protein in serum was evaluated using ELISA technology.

[0046] Among them, the inclusion criteria for patients with atherosclerotic cardiovascular disease were based on imaging examinations and clinical diagnosis of acute coronary syndrome, stable coronary heart disease, ischemic cardiomyopathy, acute myocardial infarction, ischemic stroke or peripheral atherosclerosis; patients with concurrent infections, tumors, and autoimmune diseases were excluded.

[0047] ELISA test:

[0048] 1) Sample preparation and dilution: Take an appropriate amount of serum and dilute it with sample diluent at a ratio of 1:3.

[0049] 2) Sample addition: Add 100 μL of standard and diluted serum samples to the corresponding wells and incubate at 37°C for 90 minutes;

[0050] 3) Washing: discard the supernatant and wash the plate twice with 1x washing buffer;

[0051] 4) Add biotin-labeled antibody: add 100 μL of biotin antibody working solution into the wells and incubate at 37°C for 60 minutes;

[0052] 5) Washing: discard the supernatant and wash the plate 3 times with 1x washing buffer;

[0053] 6) Add HRP-streptavidin conjugate (SABC): add 100 μL SABC working solution into the wells and incubate at 37°C for 30 minutes;

[0054] 7) Washing: discard the supernatant and wash the plate 5 times with 1x washing buffer;

[0055] 8) Add TMB substrate: add 90 μL TMB to the wells and incubate at 37°C in the dark for 10-20 minutes;

[0056] 9) Stop reaction: Add 50 μL of stop working solution to each well, measure the OD value at 450 nm using a microplate reader, draw a standard curve and calculate the sample concentration.

[0057] According to the test results, LCP1 can be detected in the serum of patients with atherosclerotic cardiovascular disease and can effectively distinguish patients with atherosclerotic cardiovascular disease from non-atherosclerotic cardiovascular disease control group ( Figure 4 ). The circulating LCP1 level of patients with atherosclerotic cardiovascular disease at admission (129.0±106.4pg / ml) was significantly higher than that of the control group (13.46±7.672pg / ml, P=0.0036), showing a high predictive accuracy with an AUC of 0.819.

[0058] The present invention found that the expression level of LCP1 gene in carotid artery tissue containing plaques is higher than that in adjacent artery tissue without plaques; LCP1 protein is significantly increased in peripheral blood serum of patients with atherosclerotic cardiovascular disease, suggesting that it can be used as a potential biomarker for atherosclerotic cardiovascular disease.

[0059] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not limitations on the implementation methods of the present invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made based on the above description. It is impossible to list all the implementation methods here. All obvious changes or modifications derived from the technical solution of the present invention are still within the protection scope of the present invention.

Claims

1. Application of a reagent for detecting the expression level of lymphocyte cytoplasmic protein 1 in a sample in the preparation of a product for diagnosing atherosclerotic cardiovascular disease.

2. The use according to claim 1, characterized in that: The reagents include: A reagent for detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in a sample; or, A reagent for detecting the protein expression level of lymphocyte cytoplasmic protein 1 in a sample.

3. The use according to claim 1, characterized in that: The product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in a sample from the subject.

4. The use according to claim 1, characterized in that: The product determines whether a subject suffers from atherosclerotic cardiovascular disease or is at risk of suffering from atherosclerotic cardiovascular disease by detecting the protein expression level of lymphocyte cytoplasmic protein 1 in a sample from the subject.

5. The use according to claim 2, characterized in that: The reagents for detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 in a sample include reagents required for detecting the mRNA expression level of lymphocyte cytoplasmic protein 1 by high-throughput RNA sequencing, RNA-in situ hybridization, digital PCR or fluorescent quantitative PCR method.

6. The use according to claim 2, characterized in that: The reagents for detecting the protein expression level of lymphocyte cytoplasmic protein 1 in the sample include the reagents required for detecting the protein expression level of the lymphocyte cytoplasmic protein 1 by chemiluminescence, immunofluorescence, protein chip, protein spectrum, immunohistochemistry, plaque tracing based on labeling technology, Western blotting or enzyme-linked immunosorbent assay.

7. The use according to claim 1, characterized in that: The sample is a serum, plasma or tissue sample.

8. The use according to claim 1, characterized in that: The product is a detection kit.

9. The use according to claim 1, characterized in that: The product is a detection chip.

10. The use according to claim 1, characterized in that: The product is a test strip.